Navigation Links
Renal sympathetic denervation improves physical and mental health in resistant hypertension
Date:8/27/2012

Munich, Germany August 26 2012: Renal sympathetic denervation improves anxiety, depression, quality of life and stress in patients with resistant hypertension, according to research presented at ESC Congress 2012 by Dr Denise Fischer from Saarland University Hospital.

Arterial hypertension is often associated with several psychological comorbidities, such as anxiety and panic disorders, leading to impaired quality of life. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension and has been shown to reduce local and whole-body sympathetic activity and blood pressure (BP).

The aim of the present study was to analyze quality of life, arousal level, anxiety and depression, sleeping quality, intensity of headache and stress tolerance in patients with resistant hypertension before and after RDN.

RDN was performed in 173 patients with resistant hypertension (BP 174/8823/13mmHg and taking a median of 5 antihypertensive drugs) aged 6310 years (53% male). Psychological status, intensity of headache, sleeping quality and stress tolerance were documented before and 3 months after RDN.

Patients rated their physical and mental state and arousal level on a 0-100% scale. Stress was induced by a multi tasking situation (Determination Task) and the total number of correct reactions, omissions and commission errors (responding to stimuli where it is not required) were recorded. Assessments were made of depression and anxiety using the Hospital Anxiety and Depression Scale (HADS) and of quality of life using the Short Form-12 Health Survey (SF-12). Insomnia and the level of regeneration achieved during sleep were assessed using a 0-100% scale and intensity of headache was measured by a visual analogous scale (VAS).

Three months after RDN was performed, office blood pressure decreased by 17/7 mmHg (p<0.01). In addition patients showed more correct reactions (p<0.0001) and less errors (p<0.05) in the multi tasking situation (Figure A shows the percentile rank (PR) score; the average percentile is 50%). Patients reported improvements in their physical state (from 55.6% to 67.2%; p<0.01), mental state (from 51.6% to 68.4%; p<0.05) and quality of life (p<0.05) (Figure B). Anxiety (p<0.0001) and depression (p<0.0001) scores decreased (Figure C). Arousal level was reduced from 49.9% to 38.9% (p<0.0001).

At baseline 32.2% of patients suffered from sleeping disorders and 60% suffered from headaches. Three months after RDN, sleeping quality improved (p<0.0001) and the intensity of headache decreased (p<0.0001) (Figure D).

"In patients with resistant hypertension overactivity of the sympathetic nervous system causes hyperarousal, leading to higher anxiety and stress levels," said Dr Fischer. "Renal denervation reduces office blood pressure and resting heart rate and does not impair psychological processes."

She added: "Renal denervation may have a positive effect on psychological processes, stress perception and processing as well as quality of life. It improves sleeping quality and may reduce the intensity of headache."

Future research should investigate long term effects of RDN on psychological processes, quality of life, rehospitalisation and mortality rates in a larger cohort of patients.


'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Newborn Screening May Miss Adrenal-Gland Disorder
2. Broken heart syndrome protects the heart from adrenaline overload
3. Renal denervation gives better outcomes than drugs in advanced heart failure
4. Renal denervation treats resistant hypertension in real world patient populations
5. Clinical insight improves treatment with new lung cancer drug
6. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
7. Exercise improves quality of life during breast cancer treatment
8. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
9. NYUCNs Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes
10. Brief training program improves resident physicians empathy with patients
11. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Venture Construction ... Classic Tournament held on June 20th at the Woodmont Country Club at 1201 ... Wings, an organization dedicated to helping service members that have been wounded in battle ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: